Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera)
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ponesimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms POINT
- Sponsors Actelion Pharmaceuticals
- 05 Sep 2017 Planned End Date changed from 31 Oct 2020 to 31 Mar 2020.
- 05 Sep 2017 Planned primary completion date changed from 31 Oct 2020 to 31 Mar 2020.
- 10 Aug 2017 Planned End Date changed from 1 May 2020 to 31 Oct 2020.